Hypersensitivity to Ultrasound Enhancing Agents: Update on ASE Recommendations on Safety and Echo Lab Policy – CME

Hypersensitivity reactions to the polyethylene glycol component of lipid stabilized UEAs have recently been recognized but are extremely rare. Sonographers, nurses, and physicians involved in the practice of echocardiography require information on related recommended changes to echo laboratory policy involving the use of UEAs. This webinar brings together experts in the field, where they will discuss:

1. The mechanisms of hypersensitivity reactions to ultrasound enhancing agents (UEA’s), including new information implicating hypersensitivity to polyethylene glycol
2. Established new contraindications to UEAs
3. New information to laboratory policy for UEAs

• Summarize the mechanisms of hypersensitivity reactions to ultrasound enhancing agents (UEAs), including new information implicating hypersensitivity to polyethylene glycol
• Recognize established and new contraindications to UEAs
• Translate this new information to laboratory policy for UEAs

This program has been designed for physicians with an interest in cardiac imaging (including, but not limited to, cardiologists, interventional cardiologists, cardiac, and vascular surgeons), and other healthcare professionals involved in echocardiography.

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education.   Northwest Imaging Forums is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  NWIF designates this live activity for a maximum of 1.0 hour AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release Date: 07/26/2022 | Expires: 07/26/2023

Faculty and Planner Disclosures:
As an accredited provider of continuing medical education, it is the policy of Northwest Imaging Forums, Inc. (NWIF) to ensure balance, independence, objectivity, and scientific rigor in all of its activities. In accordance with this policy, faculty and planners must disclose any financial relationships with commercial interests germane to program content. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of NWIF to ensure that the COI is resolved in order to ensure the integrity of the CME activity. The planner has nothing to disclose.

Jonathan R. Lindner MD, FASE, FACC

• Lantheus Medical Imaging
• GE Healthcare

Sharon L. Mulvagh MD, FRCPC, FACC, FAHA, FASE

• No Disclosures

Joan J. Olson B.S, ACS, RDCS, RVT, FASE

• No Disclosures

Anthony Montanaro MD, FACP, FAAAI, FACAI

• Merck Regeneron Teva
• AstraZeneca
• Avillion

Jonathan R. Lindner, MD, FASE, FACC

M. Lowell Edwards
Professor of Cardiology,
Oregon Health and Science
University
Portland, Oregon

Sharon L. Mulvagh, MD, FRCPC, FACC, FAHA, FASE

Professor of Medicine, Cardiologist,
Dalhousie University,
Emeritus Professor of Medicine,
Cardiovascular Diseases, Mayo Clinic
Halifax, Nova Scotia, Canada

Joan J. Olson, B.S, ACS, RDCS, RVT, FASE

Echocardiography & Nuclear
Imaging Manager
Nebraska Medicine
Omaha, Nebraska

Anthony Montanaro, MD, FACP, FAAAI, FACAI

Medical Director of Northwest
Research, Head Division of
Allergy & Immunology, OHSU
Portland, Oregon